Wells Fargo analyst Larry Biegelsen raised the firm’s price target on GE HealthCare (GEHC) to $96 from $95 and keeps an Overweight rating on the shares. The firm notes GE HealthCare delivered organic growth of about 1%, while EPS beat consensus and Wells’ estimates. Given China headwinds, management now sees lower end of 1%-2% organic growth in 2024. GE HealthCare sees the Flyrcado opportunity for revenues of over $500M annually, which the firm sees as encouraging.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare Technologies Inc. Announces Q3 2024 Results
- Morning Movers: Caterpillar and Eli Lilly sink following quarterly reports
- GE Healthcare Restructures to Enhance Imaging Solutions
- GE HealthCare reports Q3 adjusted EPS $1.14, consensus $1.05
- GE HealthCare narrows FY24 adjusted EPS view to $4.25-$4.35 from $4.20-$4.35